Showing results (41-50 of 454) with videos related to
Sort By:
Pageof 46
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|May 1, 1986
[Cardiologic findings in newly manifested type II diabetics of the diabetes intervention study]H Schmechel, S Fischer, C Lippold, et al.Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|March 17, 1999
Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT)W Leonhardt, R Horn, G Brabant, et al.European Journal of Clinical Pharmacology|January 1, 1997
Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metalsW Leonhardt, T Kurktschiev, D Meissner, et al.Diabetes Care|May 20, 1999
Increased intimal-medial thickness in newly detected type 2 diabetes: risk factorsT S Temelkova-Kurktschiev, C Koehler, W Leonhardt, et al.Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete|March 15, 1989
[Coronary heart diseases and associated risk factors in newly manifested type II diabetic patients over the course of 5 years]H Schmechel, J Schulze, M Hanefeld, et al.Arzneimittel-Forschung|April 1, 1990
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemiaS Fischer, M Hanefeld, P D Lang, et al.Journal of Lipid Research|October 1, 1996
Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approachJ Pietzsch, B Wiedemann, U Julius, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|October 29, 1996
Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjectsW Leonhardt, M Hanefeld, G Müller, et al.MMW Fortschritte Der Medizin|June 26, 2001
[The new oral antidiabetics. Type 2 diabetes under control only with tablets?]M HanefeldInternational Journal of Clinical Practice|August 15, 2001
Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitorM HanefeldPageof 46